Cannabis & Cannabinoid Research now in collaboration w/ International Association for Cannabinoid Medicines
New Rochelle, NY, May 23, 2016–Cannabis and Cannabinoid Research, the peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers, announces a new collaborative partnership with the International Association for Cannabinoid Medicines. This new collaboration promotes the missions of the Journal and Association to further the science of clinical cannabis, cannabinoids, and the endocannabinoid system, for potential therapeutic and medical application.
For the past 16 years, the International Association for Cannabinoid Medicines (IACM) has been dedicated to advancing the knowledge on cannabis, cannabinoids, the endocannabinoid system, and related topics with regard to their therapeutic potential. The IACM organizes a highly regarded biennial Conference on Cannabinoids in Medicine. "The IACM welcomes this collaboration with Cannabis and Cannabinoid Research," says Dr. Mark A. Ware, Chairman of IACM. "We are particularly excited about increasing the amount of published clinical research that will become available for healthcare professionals and decision makers."
Led by Editor-in-Chief Daniele Piomelli, PhD, PharmD, Cannabis and Cannabinoid Research provides an important open access venue for publishing the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system. The Journal publishes a broad range of human and animal studies, including basic and translational research; clinical studies; and behavioral, social, and epidemiological issues.
"We are happy to have the International Association for Cannabinoid Medicines as a partner. They have a strong commitment to furthering the knowledge of cannabis and cannabinoid medicines", says Jordan L. Schilling, Director of Open Access Publishing at Mary Ann Liebert, Inc., publishers. "The partnership will be an excellent fit for both the IACM and Cannabis and Cannabinoid Research."
About the International Association for Cannabinoid Medicines IACM's aim is to advance knowledge on cannabis, cannabinoids, the endocannabinoid system, and related topics – especially with regard to their therapeutic potential. The mission is achieved through support for research into cannabis products and the endocannabinoid system; promotion of exchange of information between researchers, health care practitioners, patients, and the public; preparation and dissemination of reliable information on the pharmacology, toxicology, and therapeutic potential of cannabis and modulators of the endocannabinoid system; monitoring and documentation of national and international developments with respect to cannabinoid therapeutics; and co-operation with other organizations and associations sharing the mission and goals of IACM.
About the Journal
Cannabis and Cannabinoid Research is the only peer-reviewed open access journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoids system. Visit the Cannabis and Cannabinoid Researchwebsite to read the latest articles published in the Journal.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Palliative Medicine, Journal of Alternative and Complementary Medicine, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.